title: Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.
abstract: We evaluated the combination of rituximab with chlorambucil in patients with mantle cell lymphoma (MCL) not eligible for aggressive therapy. Fourteen patients (male/female: 9/5) were included (two newly diagnosed, 12 relapsed/refractory). The toxicities were neutropenia, thrombopenia and infection. Nine (64%) patients responded; five (36%) achieved complete remission and four (29%) achieved partial remission. The median progression-free survival for responders was 26 months (95% CI, 4-48). Marrow polymerase chain reaction negativity was attained in seven responders. These results suggest that this schedule may have notable antitumour activity in patients with MCL, including patients in relapse after autologous stem cell transplantation.
authors.affiliation: Department of Haematology, Radiology and Clinical Biology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
authors.forename: Deborah
authors.initials: D
authors.lastname: Bauwens
authors.forename: Marie
authors.initials: M
authors.lastname: Maerevoet
authors.forename: Lucienne
authors.initials: L
authors.lastname: Michaux
authors.forename: Ivan
authors.initials: I
authors.lastname: Théate
authors.forename: Anne
authors.initials: A
authors.lastname: Hagemeijer
authors.forename: Michel
authors.initials: M
authors.lastname: Stul
authors.forename: Etienne
authors.initials: E
authors.lastname: Danse
authors.forename: Sabrina
authors.initials: S
authors.lastname: Costantini
authors.forename: Pascal
authors.initials: P
authors.lastname: Vannuffel
authors.forename: Nicole
authors.initials: N
authors.lastname: Straetmans
authors.forename: Marie-Christiane
authors.initials: MC
authors.lastname: Vekemans
authors.forename: Véronique
authors.initials: V
authors.lastname: Deneys
authors.forename: Augustin
authors.initials: A
authors.lastname: Ferrant
authors.forename: Eric
authors.initials: E
authors.lastname: Van Den Neste
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D002699:Chlorambucil; D000069283:Rituximab